menu
    • menu

    Company profile for Polaris Group

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. Our lead drug candidate, Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Polaris GroupUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10675 Sorrento Valley Rd. Suite 200, San Diego, CA 92121
    Telephone
    Telephone
    +1-858-4526688
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://polarispharma.com/contact-us/?lang=en
    Linkedin
    Linkedin
    https://www.linkedin.com/company/polaris-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Global ChemShow

    Not Confirmed

    envelop Contact Supplier

    Global ChemShow

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Er-Kim partners with Polaris Pharma for Adzodi in EMEA Market
    Er-Kim partners with Polaris Pharma for Adzodi in EMEA Market

    15 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/15/3061841/0/en/Er-Kim-Announces-Exclusive-Distribution-Agreement-with-Polaris-Pharmaceuticals-to-Commercialize-Pegargiminase-ADZODI-for-Malignant-Pleural-Mesothelioma-MPM-in-Multiple-EMEA-Markets.html

    GLOBENEWSWIRE
    15 Apr 2025
    Share Share
    Polaris Group Announced the Acquisition of Genovior Biotech
    Polaris Group Announced the Acquisition of Genovior Biotech

    21 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/22/2800400/0/en/Polaris-Group-Announced-the-Acquisition-of-Genovior-Biotech-Initiating-Dual-Engine-Growth.html

    GLOBENEWSWIRE
    21 Dec 2023
    Share Share
    Polaris Initiates Ph 3 Trial: First Patient Dosed with ADI-PEG 20/Placebo
    Polaris Initiates Ph 3 Trial: First Patient Dosed with ADI-PEG 20/Placebo

    04 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/04/2789883/0/en/Polaris-Group-Initiates-Phase-3-Trial-First-Patient-Successfully-Dosed-with-ADI-PEG-20-Placebo-plus-Gemcitabine-and-Docetaxel-for-Difficult-to-Treat-Leiomyosarcoma-LMS.html

    GLOBENEWSWIRE
    04 Dec 2023
    Share Share
    Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo
    Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo

    29 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/30/2788176/0/en/Polaris-Group-Announces-First-Patient-Successfully-Dosed-with-ADI-PEG-20-Placebo-in-Phase-2a-Non-Alcoholic-Steatohepatitis-NASH-Study.html

    GLOBENEWSWIRE
    29 Nov 2023
    Share Share
    Polaris Group Initiates Rolling Submission of BLA for ADI-PEG 20
    Polaris Group Initiates Rolling Submission of BLA for ADI-PEG 20

    16 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/17/2782330/0/en/Polaris-Group-Initiates-Rolling-Submission-of-Biologic-License-Application-BLA-for-ADI-PEG-20-with-U-S-FDA-to-Treat-Malignant-Pleural-Mesothelioma.html

    GLOBENEWSWIRE
    16 Nov 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search